Sangamo Therapeutics | 8-K: Current report
Sangamo Therapeutics | 8-K: Current report
Sangamo Therapeutics | 8-K: SANGAMO THERAPEUTICS REPORTS RECENT BUSINESS HIGHLIGHTS AND FIRST QUARTER 2024 FINANCIAL RESULTS
Sangamo Therapeutics | 8-K: Current report
Sangamo Therapeutics | DEF 14A: Definitive information statements
Sangamo Therapeutics | PRE 14A: Preliminary proxy statements relating to merger or acquisition
Sangamo Therapeutics | 8-K: Current report
Sangamo Therapeutics | 8-K: SANGAMO THERAPEUTICS REPORTS RECENT BUSINESS HIGHLIGHTS AND FOURTH QUARTER AND FULL YEAR 2023 FINANCIAL RESULTS
Sangamo Therapeutics | 8-K: Current report
Sangamo Therapeutics | 8-K: Current report
Sangamo Therapeutics | 8-K: Current report
Sangamo Therapeutics | 8-K: Current report
Sangamo Therapeutics | 8-K: SANGAMO THERAPEUTICS ANNOUNCES STRATEGIC UPDATE AND REPORTS THIRD QUARTER 2023 FINANCIAL RESULTS
Sangamo Therapeutics | S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plans
Sangamo Therapeutics | 8-K: SANGAMO THERAPEUTICS REPORTS RECENT BUSINESS HIGHLIGHTS AND SECOND QUARTER 2023 FINANCIAL RESULTS
Sangamo Therapeutics | 8-K: Current report
Sangamo Therapeutics | 8-K: SANGAMO THERAPEUTICS ANNOUNCES STRATEGIC UPDATE AND REPORTS PRELIMINARY FIRST QUARTER 2023 FINANCIAL RESULTS
Sangamo Therapeutics | DEF 14A: Definitive proxy statements
Sangamo Therapeutics | PRE 14A: Preliminary proxy statement not related to a contested matter or merger/acquisition
Sangamo Therapeutics | 8-K: Current report
No Data